Jubilant Pharmova Limited (JUBLPHARMA.NS)
INR 1085.05
(-0.42%)
INR 1085.05
(-0.42%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 67.02 Billion | 62.19 Billion | 60.59 Billion | 59.63 Billion | 89.76 Billion | 89.97 Billion |
| Cost of Revenue | 47.38 Billion | 18.77 Billion | 17.86 Billion | 17.53 Billion | 34.54 Billion | 38.21 Billion |
| Gross Profit | 19.64 Billion | 43.41 Billion | 42.72 Billion | 42.1 Billion | 55.22 Billion | 51.75 Billion |
| Operating Expenses | 14.45 Billion | 41.19 Billion | 34.47 Billion | 30.91 Billion | 40.34 Billion | 37.93 Billion |
| Selling, General and Administrative Expenses | 14.45 Billion | 3.75 Billion | 4.01 Billion | 3.81 Billion | 4.78 Billion | 4.85 Billion |
| Research and Development Expenses | - | - | - | - | 185.05 Million | 202.2 Million |
| Other Expenses | - | 383.3 Million | 86.9 Million | 67.18 Million | 115.14 Million | 125.48 Million |
| Cost and Expenses | 61.84 Billion | 59.97 Billion | 52.34 Billion | 48.45 Billion | 74.88 Billion | 76.15 Billion |
| Operating Income | 5.18 Billion | 3.74 Billion | 8.39 Billion | 11.44 Billion | 12.38 Billion | 13.82 Billion |
| Interest Expense | 2.72 Billion | 1.88 Billion | 1.38 Billion | 1.73 Billion | 2.72 Billion | 2.06 Billion |
| Income Tax Expense | 978 Million | 926.6 Million | 2.17 Billion | 2.97 Billion | 3.12 Billion | 3.26 Billion |
| Earnings before Tax | 1.7 Billion | 277.8 Million | 6.3 Billion | 8.71 Billion | 12.1 Billion | 9.03 Billion |
| Net Income | 771 Million | -609.8 Million | 4.13 Billion | 8.35 Billion | 8.98 Billion | 5.74 Billion |
| Earnings Per Share Basic | 4.86 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 |
| Earnings Per Share Diluted | 4.85 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 |
| Weighted Average Shares Outstanding | 158.5 Million | 159.14 Million | 159.17 Million | 159.26 Million | 159.27 Million | 159.12 Million |
| Weighted Average Shares Outstanding (Diluted) | 158.85 Million | 159.14 Million | 159.17 Million | 159.26 Million | 159.27 Million | 159.12 Million |
| Gross Margin | 0.29 | 0.70 | 0.71 | 0.71 | 0.62 | 0.58 |
| EBIT Margin | 0.12 | 0.13 | 0.19 | 0.26 | 0.22 | 0.20 |
| Profit Margin | 0.01 | -0.01 | 0.07 | 0.14 | 0.10 | 0.06 |
| EBITDA | 8 Billion | 7.57 Billion | 11.67 Billion | 13.92 Billion | 15.52 Billion | 14.93 Billion |
| Earnings Before Tax Margin | 0.08 | 0.06 | 0.14 | 0.19 | 0.14 | 0.15 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 17.42 Billion | 17.31 Billion | 67.02 Billion | 17.58 Billion | 16.65 Billion | 16.66 Billion |
| Cost of Revenue | 5.54 Billion | 12.05 Billion | 47.38 Billion | 11.83 Billion | 5.35 Billion | 5.57 Billion |
| Gross Profit | 11.87 Billion | 5.26 Billion | 19.64 Billion | 5.75 Billion | 11.29 Billion | 11.09 Billion |
| Operating Expenses | 9.89 Billion | 4.6 Billion | 14.45 Billion | 4.04 Billion | 10.05 Billion | 9.64 Billion |
| Selling, General and Administrative Expenses | 3.43 Billion | 3.65 Billion | - | 4.04 Billion | 3.41 Billion | 3.49 Billion |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 9.89 Billion | -953 Million | 687 Million | 144 Million | 358 Million | 99 Million |
| Cost and Expenses | 15.44 Billion | 16.66 Billion | 61.84 Billion | 15.88 Billion | 15.41 Billion | 15.21 Billion |
| Operating Income | 1.98 Billion | 655 Million | 5.18 Billion | 1.7 Billion | 1.72 Billion | 1.64 Billion |
| Interest Expense | 610 Million | 710 Million | 2.72 Billion | 730 Million | 713 Million | 661 Million |
| Income Tax Expense | 419 Million | 179 Million | 978 Million | 81 Million | 346 Million | 359 Million |
| Earnings before Tax | 1.44 Billion | 4.99 Billion | 1.46 Billion | -571 Million | 1.01 Billion | 980 Million |
| Net Income | 1.02 Billion | 4.82 Billion | 771 Million | -586 Million | 668 Million | 625 Million |
| Earnings Per Share Basic | 6.47 | 30.51 | - | -3.68 | 4.19 | 3.92 |
| Earnings Per Share Diluted | 6.46 | 30.35 | - | -3.68 | 4.19 | 3.92 |
| Weighted Average Shares Outstanding | 158.88 Million | 158 Million | 159.28 Million | 159.28 Million | 159.28 Million | 159.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 159.13 Million | 158.84 Million | 159.28 Million | 159.28 Million | 159.28 Million | 159.28 Million |
| Gross Margin | 0.68 | 0.30 | 0.29 | 0.33 | 0.68 | 0.67 |
| EBIT Margin | 0.17 | 0.09 | - | 0.15 | 0.16 | 0.16 |
| Profit Margin | 0.06 | 0.28 | 0.01 | -0.03 | 0.04 | 0.04 |
| EBITDA | 2.96 Billion | 1.56 Billion | - | 2.71 Billion | 2.66 Billion | 2.6 Billion |
| Earnings Before Tax Margin | 0.11 | 0.04 | 0.08 | 0.10 | 0.10 | 0.10 |
300220
CTRL
GR1T
OXBR
SUPREMEIND
VPLM